Følg
Pier Federico Gherardini
Pier Federico Gherardini
Verifisert e-postadresse på stanford.edu
Tittel
Sitert av
Sitert av
År
Systemic immunity is required for effective cancer immunotherapy
MH Spitzer, Y Carmi, NE Reticker-Flynn, SS Kwek, D Madhireddy, ...
Cell 168 (3), 487-502. e15, 2017
9472017
Highly multiplexed simultaneous detection of RNAs and proteins in single cells
AP Frei, FA Bava, ER Zunder, EWY Hsieh, SY Chen, GP Nolan, ...
Nature methods 13 (3), 269-275, 2016
3682016
High response rate to PD-1 blockade in desmoplastic melanomas
Z Eroglu, JM Zaretsky, S Hu-Lieskovan, DW Kim, A Algazi, DB Johnson, ...
Nature 553 (7688), 347-350, 2018
3322018
Epigenomic-guided mass cytometry profiling reveals disease-specific features of exhausted CD8 T cells
B Bengsch, T Ohtani, O Khan, M Setty, S Manne, S O’Brien, PF Gherardini, ...
Immunity 48 (5), 1029-1045. e5, 2018
3052018
AMBRA1 links autophagy to cell proliferation and tumorigenesis by promoting c-Myc dephosphorylation and degradation
V Cianfanelli, C Fuoco, M Lorente, M Salazar, F Quondamatteo, ...
Nature cell biology 17 (1), 20-30, 2015
2862015
An interactive reference framework for modeling a dynamic immune system
MH Spitzer, PF Gherardini, GK Fragiadakis, N Bhattacharya, RT Yuan, ...
Science 349 (6244), 1259425, 2015
2692015
CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma: an open-label …
MH O'Hara, EM O'Reilly, G Varadhachary, RA Wolff, ZA Wainberg, AH Ko, ...
The lancet oncology 22 (1), 118-131, 2021
2482021
Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial
LJ Padrón, DM Maurer, MH O’Hara, EM O’Reilly, RA Wolff, ZA Wainberg, ...
Nature medicine 28 (6), 1167-1177, 2022
2302022
Convergent evolution of enzyme active sites is not a rare phenomenon
PF Gherardini, MN Wass, M Helmer-Citterich, MJE Sternberg
Journal of molecular biology 372 (3), 817-845, 2007
1672007
Comprehensive immune monitoring of clinical trials to advance human immunotherapy
FJ Hartmann, J Babdor, PF Gherardini, EAD Amir, K Jones, B Sahaf, ...
Cell reports 28 (3), 819-831. e4, 2019
1212019
Multiplexed detection and quantification of nucleic acids in single-cells
AP Frei, GP Nolan, PF Gherardini, FA Bava
US Patent App. 14/875,454, 2016
1012016
Structure-based function prediction: approaches and applications
PF Gherardini, M Helmer-Citterich
Briefings in Functional Genomics and Proteomics 7 (4), 291-302, 2008
1012008
Deep proteomics of breast cancer cells reveals that metformin rewires signaling networks away from a pro-growth state
F Sacco, A Silvestri, D Posca, S Pirrò, PF Gherardini, L Castagnoli, ...
Cell Systems 2 (3), 159-171, 2016
962016
Phosphoproteomic Analysis of Differentiating Leishmania Parasites Reveals a Unique Stage-Specific Phosphorylation Motif
P Tsigankov, PF Gherardini, M Helmer-Citterich, GF Späth, D Zilberstein
Journal of proteome research 12 (7), 3405-3412, 2013
932013
Regulation dynamics of Leishmania differentiation: deconvoluting signals and identifying phosphorylation trends
P Tsigankov, PF Gherardini, M Helmer-Citterich, GF Späth, PJ Myler, ...
Molecular & Cellular Proteomics 13 (7), 1787-1799, 2014
892014
Single-cell systems-level analysis of human Toll-like receptor activation defines a chemokine signature in patients with systemic lupus erythematosus
WE O'Gorman, EWY Hsieh, ES Savig, PF Gherardini, JD Hernandez, ...
Journal of Allergy and Clinical Immunology 136 (5), 1326-1336, 2015
842015
Exploring the diversity of SPRY/B30. 2-mediated interactions
L Perfetto, PF Gherardini, NE Davey, F Diella, M Helmer-Citterich, ...
Trends in biochemical sciences 38 (1), 38-46, 2013
802013
Abstract CT004: A Phase Ib study of CD40 agonistic monoclonal antibody APX005M together with gemcitabine (Gem) and nab-paclitaxel (NP) with or without nivolumab (Nivo) in …
MH O'Hara, EM O'Reilly, M Rosemarie, G Varadhachary, ZA Wainberg, ...
Cancer research 79 (13_Supplement), CT004-CT004, 2019
562019
Phospho3D 2.0: an enhanced database of three-dimensional structures of phosphorylation sites
A Zanzoni, D Carbajo, F Diella, PF Gherardini, A Tramontano, ...
Nucleic acids research 39 (suppl_1), D268-D271, 2010
552010
Phospho3D: a database of three-dimensional structures of protein phosphorylation sites
A Zanzoni, G Ausiello, A Via, PF Gherardini, M Helmer-Citterich
Nucleic Acids Research 35 (suppl_1), D229-D231, 2007
542007
Systemet kan ikke utføre handlingen. Prøv på nytt senere.
Artikler 1–20